Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Ludwig-Maximilians - University of Munich clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Germany, Denmark, Netherlands and Austria registers with Ludwig-Maximilians - University of Munich as lead sponsor. Synced 14 Nov 2026
24Current trials
17Recruiting now
2Drugs in these trials
4Trial registers
At a glance

Ludwig-Maximilians - University of Munich is the lead sponsor of 24 current clinical trials in our Germany, Denmark, Netherlands and Austria registers. 17 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Dornase Alfa and Semaglutide. The most-studied condition is Quality of Life.

ClinicalTrials.gov trials by status

  • Recruiting1771%
  • Not yet open28%
  • Active, closed521%

Trials by phase

  • Observational1667%
  • Not applicable729%
  • Phase 214%
01

Clinical trials sponsored by Ludwig-Maximilians - University of Munich

24 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy
NCT05842928 · ClinicalTrials.gov ↗ · Deprescriptions, Antidepressive Agents, Antipsychotic Agents
Not applicable Recruiting 2023-03 Germany
Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE)
NCT03792854 · ClinicalTrials.gov ↗ · Anal Cancer, Quality of Life, Chemoradiation
Observational Recruiting 2018-12 Germany
Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer
NCT03731130 · ClinicalTrials.gov ↗ · Rectal Cancer, Quality of Life, Radiation Therapy
Observational Recruiting 2018-10 Germany
A Longitudinal Natural History Study of OPA1-Associated Autosomal-Dominant Optic Atrophy
NCT07729982 · ClinicalTrials.gov ↗ · OPA1 Gene Mutation, Optic Atrophy, Autosomal Dominant
Observational Recruiting 2026-07 Germany
Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant or Definitive Chemoradiation in Patients With Esophageal Cancer
NCT03712774 · ClinicalTrials.gov ↗ · Quality of Life, Chemoradiation, Esophageal Cancer
Observational Recruiting 2018-10 Germany
HoLEP-ThuLEP - Comparing Lasers for BPH Surgery
NCT07565961 · ClinicalTrials.gov ↗ · BPH (Benign Prostatic Hyperplasia)
Not applicable Recruiting 2026-09 Germany
Dementia-friendly Apothecaries as a Resource for Mental Heath in the Elderly
NCT07504965 · ClinicalTrials.gov ↗ · Mild Cognitive Impairment, Mild Dementia
Observational Recruiting 2025-07 Germany
Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)
NCT05880524 · ClinicalTrials.gov ↗ · Ischemic Stroke, Inflammatory Response
Phase 2 Recruiting 2026-10 Germany
Prospective Cohort With Incident Stroke
NCT01364168 · ClinicalTrials.gov ↗ · Ischemic Stroke
Observational Recruiting 2011-02 Germany
Plaque Imaging in Routine Care to Detect Intraplaque Hemorrhage
NCT06749106 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Observational Recruiting 2025-01 Germany
Amyloid-β Clearance Mechanisms in Alzheimer's Disease
NCT05059158 · ClinicalTrials.gov ↗ · Alzheimer's Disease (AD)
Observational Recruiting 2021-06 Germany
Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma
NCT03253536 · ClinicalTrials.gov ↗ · Hepatocellular Cancer, Quality of Life, Stereotactic Body Radiation Therapy
Observational Recruiting 2017-07 Germany
PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke
NCT06121336 · ClinicalTrials.gov ↗ · Stroke, Stroke, Acute, Stroke, Ischemic
Observational Recruiting 2023-03 Germany
Pairing Subjective Patient Rating and DBS Programming
NCT07336199 · ClinicalTrials.gov ↗ · Parkinson's Disease (PD)
Observational Recruiting 2024-12 Germany
Preoperative Physical Activity Before Radical Cystectomy and the Impact on Morbidity
NCT06806059 · ClinicalTrials.gov ↗ · Urothelial Carcinoma Bladder
Not applicable Recruiting 2024-11 Germany
German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q)
NCT06711952 · ClinicalTrials.gov ↗ · Alzheimer Disease, Subjective Cognitive Decline
Not applicable Recruiting 2023-02 Germany
Assessment of Daily Stressors in Children With Depressive Symptoms for the Development of a Gamified Emotion Regulation App
NCT07159347 · ClinicalTrials.gov ↗ · Depressive Disorder, Depression in Children, Depressive Symptoms
Observational Recruiting 2025-09 Germany
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors
NCT07762820 · ClinicalTrials.gov ↗ · Bladder Cancer, Bladder Cancer TNM Staging Primary Tumor (T) T1
Not applicable Not yet open 2026-09 Germany, Denmark
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
NCT07586150 · ClinicalTrials.gov ↗ · Severe Mental Illness, Depression / Major Depressive Disorder, Bipolar Disorder (BD)
Not applicable Not yet open 2028-10 Germany, Netherlands, Austria
Observational Study on Determinants of Dementia After Stroke
NCT01334749 · ClinicalTrials.gov ↗ · Ischemic Stroke, Hemorrhagic Stroke
Observational Active, closed 2011-04 Germany
Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer
NCT04246203 · ClinicalTrials.gov ↗ · Pancreas Cancer
Observational Active, closed 2021-12 Germany
Decision-making, Ethical Consent, and Interactive Dialogue in Ongoing Neurocognitive Decline - DECISION
NCT07514520 · ClinicalTrials.gov ↗ · Alzheimer Disease, Neurodegenerative Diseases
Observational Active, closed 2025-10 Germany
The Effect of a Structured Strength and Endurance Training Program on Quality of Life, Fitness, Blood Parameters and Survival in Prostate Cancer Patients
NCT07126860 · ClinicalTrials.gov ↗ · Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer (Post Prostatectomy)
Not applicable Active, closed 2024-05 Germany
Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma
NCT06642506 · ClinicalTrials.gov ↗ · Esophagus Adenocarcinoma, Esophagus Cancer, Metabolome
Observational Active, closed 2024-10 Germany

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Ludwig-Maximilians - University of Munich trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Ludwig-Maximilians - University of Munich trials

50 conditions
Quality of Life4Chemoradiation3Ischemic Stroke3Alzheimer Disease2Deprescriptions1Antidepressive Agents1Antipsychotic Agents1Analgesics, Opioid1Anal Cancer1Bladder Cancer1Bladder Cancer TNM Staging Primary Tumor (T) T11Rectal Cancer1Radiation Therapy1Severe Mental Illness1Depression / Major Depressive Disorder1Bipolar Disorder (BD)1Schizophrenia1Hemorrhagic Stroke1OPA1 Gene Mutation1Optic Atrophy, Autosomal Dominant1Pancreas Cancer1Esophageal Cancer1BPH (Benign Prostatic Hyperplasia)1Mild Cognitive Impairment1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in Germany2417
Clinical trials in Denmark10
Clinical trials in Netherlands10
Clinical trials in Austria10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Quality of Life

SponsorTrials
University Hospital, Clermont-Ferrand4
Mucosa Innovations4
Oslo University Hospital3
Region Örebro County3
Saglik Bilimleri Universitesi3
Hospital Universitari de Bellvitge2
Silimed Industria de Implantes Ltda2
Centre Hospitalier de Colmar1
CEU San Pablo University1
Université Libre de Bruxelles1

Sponsors with the most current trials registered for this condition.

06

Questions about Ludwig-Maximilians - University of Munich trials

How many clinical trials does Ludwig-Maximilians - University of Munich sponsor?

Ludwig-Maximilians - University of Munich is the lead sponsor of 24 current trials on ClinicalTrials.gov in our Germany, Denmark, Netherlands and Austria registers, as of the registry sync on 14 November 2026. Completed and withdrawn studies are not counted.

Are Ludwig-Maximilians - University of Munich trials recruiting?

Yes. 17 of its 24 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Ludwig-Maximilians - University of Munich testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Dornase Alfa (1) and Semaglutide (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 14 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.